f APP Gene-based Strategies to Combat Alzheimer's Disease in Down Syndrome

References

1. BallardC. MobleyW. HardyJ. WilliamsG. CorbettA. Dementia in Down’s syndrome.Lancet Neurol.201615662263610.1016/S1474‑4422(16)00063‑6 27302127
   [Google Scholar]
2. SelkoeD.J. HardyJ. The amyloid hypothesis of Alzheimer’s disease at 25 years.EMBO Mol. Med.20168659560810.15252/emmm.201606210 27025652
   [Google Scholar]
3. DoranE. KeatorD. HeadE. PhelanM.J. KimR. TotoiuM. BarrioJ.R. SmallG.W. PotkinS.G. LottI.T. Down syndrome, partial trisomy 21, and absence of Alzheimer’s disease: The role of APP.J. Alzheimers Dis.201756245947010.3233/JAD‑160836 27983553
   [Google Scholar]
4. ChenX.Q. SalehiA. PearnM.L. OverkC. NguyenP.D. KleschevnikovA.M. MaccecchiniM. MobleyW.C. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.Alzheimers Dement.202117227129210.1002/alz.12185 32975365
   [Google Scholar]
5. BandyopadhyayS. CahillC. BalleidierA. HuangC. LahiriD.K. HuangX. RogersJ.T. Novel 5′ untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: Implications for down syndrome and Alzheimer’s disease.PLoS One201387e6597810.1371/journal.pone.0065978 23935819
   [Google Scholar]
6. GalaskoD. FarlowM.R. LuceyB.P. HonigL.S. ElbertD. BatemanR. MomperJ. ThomasR.G. RissmanR.A. PaJ. AslanyanV. BalasubramanianA. WestT. MaccecchiniM. FeldmanH.H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease.Alzheimers Res. Ther.202416115110.1186/s13195‑024‑01490‑z 38970127
   [Google Scholar]
7. ChangJ.L. HinrichA.J. RomanB. NorrbomM. RigoF. MarrR.A. NorstromE.M. HastingsM.L. Targeting amyloid-β precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-β production.Mol. Ther.20182661539155110.1016/j.ymthe.2018.02.029 29628304
   [Google Scholar]
8. HungC. FertanE. LiveseyF.J. KlenermanD. PataniR. APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer’s disease.Brain202414772325233310.1093/brain/awae092 38527856
   [Google Scholar]
9. NordvallG. LundkvistJ. SandinJ. Gamma-secretase modulators: A promising route for the treatment of Alzheimer’s disease.Front. Mol. Neurosci.202316127974010.3389/fnmol.2023.1279740 37908487
   [Google Scholar]
10. RynearsonK.D. PonnusamyM. PrikhodkoO. XieY. ZhangC. NguyenP. HugB. SawaM. BeckerA. SpencerB. FlorioJ. ManteM. SalehiB. AriasC. GalaskoD. HeadB.P. JohnsonG. LinJ.H. DuddyS.K. RissmanR.A. MobleyW.C. ThinakaranG. TanziR.E. WagnerS.L. Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention.J. Exp. Med.20212184e2020256010.1084/jem.20202560 33651103
    [Google Scholar]
11. WagnerS.L. RynearsonK.D. DuddyS.K. ZhangC. NguyenP.D. BeckerA. VoU. MasliahD. MonteL. KleeJ.B. EchmalianC.M. XiaW. QuintiL. JohnsonG. LinJ.H. KimD.Y. MobleyW.C. RissmanR.A. TanziR.E. Pharmacological and toxicological properties of the potent oral γ-secretase modulator BPN-15606.J. Pharmacol. Exp. Ther.20173621314410.1124/jpet.117.240861 28416568
    [Google Scholar]
12. PrikhodkoO. RynearsonK.D. SekhonT. ManteM.M. NguyenP.D. RissmanR.A. TanziR.E. WagnerS.L. The GSM BPN-15606 as a potential candidate for preventative therapy in Alzheimer’s disease.J. Alzheimers Dis.20207341541155410.3233/JAD‑190442 31958080
    [Google Scholar]
13. ChenX.Q. BeckerA. AlbayR. NguyenP.D. KarachentsevD. RobertsA.J. RynearsonK.D. TanziR.E. MobleyW.C. γ-secretase modulator BPN15606 reduced Aβ42 and Aβ40 and countered alzheimer-related pathologies in a mouse model of down syndrome.Ann. Neurol.202496239040410.1002/ana.26958 38747498
    [Google Scholar]
14. CummingsJ. OsseA.M.L. CammannD. PowellJ. ChenJ. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease.BioDrugs202438152210.1007/s40259‑023‑00633‑2 37955845
    [Google Scholar]
15. BelichenkoP.V. MadaniR. Rey-BelletL. PihlgrenM. BeckerA. PlassardA. VuillermotS. GiriensV. NoshenyR.L. KleschevnikovA.M. VallettaJ.S. BengtssonS.K. LinkeG.R. MaloneyM.T. HickmanD.T. ReisP. GranetA. MlakiD. Lopez-DeberM.P. DoL. SinghalN. MasliahE. PearnM.L. PfeiferA. MuhsA. MobleyW.C. An anti-β-amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.PLoS One2016113e015247110.1371/journal.pone.0152471 27023444
    [Google Scholar]
16. RafiiM.S. SolO. MobleyW.C. DelprettiS. SkotkoB.G. BurkeA.D. SabbaghM.N. YuanS.H. RissmanR.A. PulsiferM. EvansC. EvansA.C. BethG. FournierN. GrayJ.A. Dos SantosA.M. HlivaV. VukicevicM. Kosco-VilboisM. StrefferJ. PfeiferA. FeldmanH.H. Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with down syndrome: A phase 1b randomized clinical trial.JAMA Neurol.202279656557410.1001/jamaneurol.2022.0983 35532913
    [Google Scholar]